View Item 

Show simple item record

Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension

dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorGladue, Heatheren_US
dc.contributor.authorChannick, Richarden_US
dc.contributor.authorChung, Lorindaen_US
dc.contributor.authorDistler, Oliveren_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorHachulla, Ericen_US
dc.contributor.authorHumbert, Marcen_US
dc.contributor.authorLangleben, Daviden_US
dc.contributor.authorMathai, Stephen C.en_US
dc.contributor.authorSaggar, Rajeeven_US
dc.contributor.authorVisovatti, Scotten_US
dc.contributor.authorAltorok, Nezamen_US
dc.contributor.authorTownsend, Whitneyen_US
dc.contributor.authorFitzGerald, Johnen_US
dc.contributor.authorMcLaughlin, Vallerie V.en_US
dc.date.accessioned2013-12-04T18:57:18Z
dc.date.available2015-01-05T13:54:43Zen_US
dc.date.issued2013-12en_US
dc.identifier.citationKhanna, Dinesh; Gladue, Heather; Channick, Richard; Chung, Lorinda; Distler, Oliver; Furst, Daniel E.; Hachulla, Eric; Humbert, Marc; Langleben, David; Mathai, Stephen C.; Saggar, Rajeev; Visovatti, Scott; Altorok, Nezam; Townsend, Whitney; FitzGerald, John; McLaughlin, Vallerie V. (2013). "Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension." Arthritis & Rheumatism 65(12): 3194-3201.en_US
dc.identifier.issn0004-3591en_US
dc.identifier.issn1529-0131en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/101802
dc.publisherRAND Corporationen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleRecommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertensionen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/101802/1/art38172.pdf
dc.identifier.doi10.1002/art.38172en_US
dc.identifier.sourceArthritis & Rheumatismen_US
dc.identifier.citedreferenceBae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, et al, for the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators. Baseline characteristics and follow‐up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis—results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335 – 42.en_US
dc.identifier.citedreferenceAlarcon‐Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp G, editors. Mixed connective tissue disease and anti‐nuclear antibodies. Amsterdam: Elsevier; 1987. p. 33 – 40.en_US
dc.identifier.citedreferenceSharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148 – 59.en_US
dc.identifier.citedreferenceKahn MF, Appelboom T. Syndrom de Sharp. In: Kahn MF, Peltier AP, Meyer O, Piette JC, editors. Les maladies systemiques. 3rd ed. Paris: Flammarion; 1991. p. 545 – 556.en_US
dc.identifier.citedreferenceKasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti‐nuclear antibodies. Amsterdam: Elsevier; 1987. p. 41 – 8.en_US
dc.identifier.citedreferenceHachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al, and the ItinerAIR‐Sclerodermie Study Group. The three‐year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831 – 9.en_US
dc.identifier.citedreferenceYoshida S. Pulmonary arterial hypertension in connective tissue diseases. Allergol Int 2011; 60: 405 – 9.en_US
dc.identifier.citedreferenceHoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30: 369 – 75.en_US
dc.identifier.citedreferenceTunariu N, Gibbs SJ, Win Z, Gin‐Sing W, Graham A, Gishen P, et al. Ventilation‐perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48: 680 – 4.en_US
dc.identifier.citedreferenceCoghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al, on behalf of the DETECT Study Group. Evidence‐based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2013. E‐pub ahead of print.en_US
dc.identifier.citedreferenceMontani D, Savale L, Natali D, Jais X, Herve P, Garcia G, et al. Long‐term response to calcium‐channel blockers in non‐idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 1898 – 907.en_US
dc.identifier.citedreferenceSaggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, et al. Exercise‐induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum 2010; 62: 3741 – 50.en_US
dc.identifier.citedreferenceWalker UA, Tyndall A, Czirjak L, Denton C, Farge‐Bancel D, Kowal‐Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754 – 63.en_US
dc.identifier.citedreferenceLaunay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren's syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86: 299 – 315.en_US
dc.identifier.citedreferenceHumbert M, Gerry Coghlan J, Khanna D. Early detection and management of pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 306 – 12.en_US
dc.identifier.citedreferenceThe Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little Brown; 1994. p. 253 – 6.en_US
dc.identifier.citedreferenceRajaram S, Swift AJ, Capener D, Elliot CA, Condliffe R, Davies C, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. J Rheumatol 2012; 39: 1265 – 74.en_US
dc.identifier.citedreferenceStupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515 – 24.en_US
dc.identifier.citedreferenceAllanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N‐terminal pro–brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284 – 91.en_US
dc.identifier.citedreferenceThakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D, et al. N‐terminal pro‐brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case‐control study. Arthritis Res Ther 2012; 14: R143.en_US
dc.identifier.citedreferenceHachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792 – 800.en_US
dc.identifier.citedreferenceMeune C, Avouac J, Airo P, Beretta L, Dieude P, Wahbi K, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63: 2790 – 6.en_US
dc.identifier.citedreferenceGladue H, Steen V, Allanore Y, Saggar R, Saggar R, Maranian P, et al. Combination of echocardiographic and pulmonary function test measures improves sensitivity for the diagnosis of systemic sclerosis‐associated pulmonary arterial hypertension: analysis of two cohorts. J Rheumatol 2013. E‐pub 8/21/13.en_US
dc.identifier.citedreferencePhung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 682 – 91.en_US
dc.identifier.citedreferenceCiurzynski M, Bienias P, Irzyk K, Rymarczyk Z, Kostrubiec M, Lichodziejewska B, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension in patients with systemic sclerosis. Eur Heart J 2010; 31: 869 – 70.en_US
dc.identifier.citedreferenceJansa P, Becvar R, Ambroz D, Palecek T, Tomcik M, Skacelova S, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clin Rheumatol 2012; 31: 557 – 61.en_US
dc.identifier.citedreferenceAvouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290 – 8.en_US
dc.identifier.citedreferenceRudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685 – 713.en_US
dc.identifier.citedreferenceNair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum 2011; 41: 95 – 105.en_US
dc.identifier.citedreferenceSingh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625 – 39.en_US
dc.identifier.citedreferenceMukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461 – 6.en_US
dc.identifier.citedreferenceHumbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long‐term survival. Arthritis Rheum 2011; 63: 3522 – 30.en_US
dc.identifier.citedreferenceBurdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long‐term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42: 899 – 909.en_US
dc.identifier.citedreferenceRuiz‐Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013; 12: 410 – 5.en_US
dc.identifier.citedreferenceUdayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis–relation with the duration of the disease. Int J Cardiol 2008; 127: 410 – 2.en_US
dc.identifier.citedreferenceCondliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease‐associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151 – 7.en_US
dc.identifier.citedreferenceMcLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573 – 619.en_US
dc.identifier.citedreferenceGalie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al, Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219 – 63.en_US
dc.identifier.citedreferenceBadesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55 – 66.en_US
dc.identifier.citedreferenceFitch K, Bernstein SJ, Aguilar MS, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA appropriateness method user's manual. Santa Monica (CA): RAND Corporation; 2001.en_US
dc.identifier.citedreferenceKhanna D, Khanna PP, FitzGerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2. Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 – 61.en_US
dc.identifier.citedreferenceKhanna D, FitzGerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1. Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431 – 46.en_US
dc.identifier.citedreferenceGrossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis [published erratum appears in Arthritis Care Res (Hoboken) 2012;64:464]. Arthritis Care Res (Hoboken) 2010; 62: 1515 – 26.en_US
dc.identifier.citedreferenceSaag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762 – 84.en_US
dc.identifier.citedreferenceGladue H, Altorok N, Townsend W, McLaughlin V, Khanna D. Screening and diagnostic modalities for connective tissue disease‐associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum 2013. E‐pub 9/10/13.en_US
dc.identifier.citedreferenceWhiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.en_US
dc.identifier.citedreferenceWhiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529 – 36.en_US
dc.identifier.citedreferenceAtkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.en_US
dc.identifier.citedreferenceSchunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al, GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106 – 10.en_US
dc.identifier.citedreferenceNational Conference on chronic disease. Public Health Nurs 1951; 43: 344.en_US
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 90.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art38172.pdf
Size:
84.78KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.